Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses.
Somagenetix has raised $11.7M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
Somagenetix's investors include Schroders Capital, Verve Ventures, Zurcher Kantonal Bank, VI Partners.
Somagenetix is headquartered in Zurich, Switzerland.
Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses.
Somagenetix is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Somagenetix — Funding & Investors." VCBacked, October 8, 2024, https://www.vcbacked.co/company/somagenetix. Accessed October 28, 2026.
VCBacked. (2024). Somagenetix — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/somagenetix
{{cite web |title=Somagenetix — Funding & Investors |url=https://www.vcbacked.co/company/somagenetix |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated